Recent Updates
Recently added Catalysts

Kristalose

Phase 1

Bowel Evacuant Prior to Colonoscopy | Small molecule | Gastrointestinal |Cumberland Pharmaceuticals Inc.|Last Updated: Oct 6, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

Clinical trial landscape

Kristalose · 1 trial · 1 indication

Phase 1 1
NCT01256541Kristalose as Bowel Evacuant Prior to ColonoscopyBowel Evacuant Prior to Colonoscopy
COMPLETED20 Analytics
PHASE1COMPLETED
Kristalose as Bowel Evacuant Prior to Colonoscopy
Bowel Evacuant Prior to ColonoscopyUnlock trial analytics

Study Endpoints

Primary Endpoints

Hydrogen and Methane Gas Production
3 months

To evaluate the primary objective of hydrogen and methane gas production as measured by: • Pre- and post-dose breath analysis for hydrogen and methane gas.

Secondary Endpoints

Efficacy
3 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
KristaloseEXPERIMENTALKristalose as Bowel Evacuant

Interventions

NameTypeDescription
KristaloseDRUGThe dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: Patients requiring bowel evacuation for colonoscopy Exclusion Criteria: 1. Patients with galactosemia (galactose-sensitive diet). 2. Patients known to be hypersensitive to any of the components of Kristalose. 3. Patients with possible bowel obstruction, previous colonic surger...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Kristalose

What is Kristalose used for?

Kristalose is a small molecule being studied as a bowel evacuant prior to colonoscopy. It is intended to prepare the bowel for the procedure. The drug is in clinical development for this gastrointestinal indication and is not yet approved for this use.

Who makes Kristalose?

Kristalose is being developed by Cumberland Pharmaceuticals Inc., a company traded on the Nasdaq under the ticker CPIX. The company is conducting clinical research on the drug for use as a bowel evacuant prior to colonoscopy.

What phase is Kristalose in?

Kristalose is in Phase 1 clinical development as a bowel evacuant prior to colonoscopy. A Phase 1 trial has been completed, and the drug remains investigational for this indication. It is not FDA approved for this use.

What clinical trials is Kristalose in?

Kristalose has one completed clinical trial, NCT01256541, titled 'Kristalose as Bowel Evacuant Prior to Colonoscopy.' This Phase 1 study enrolled 20 participants in the United States and was not randomized, double-blind, or controlled.

Is Kristalose the same as any other drug?

Kristalose is the brand name for lactulose, a synthetic sugar used as a laxative. In the context of this clinical trial, it is being evaluated specifically as a bowel evacuant prior to colonoscopy. The drug is not approved for this particular use.